6.2 Risk-benefit analysis in clinical trials

Risk-benefit analysis in clinical trials is crucial for ensuring participant safety and scientific value. It balances potential risks against expected benefits, guided by ethical principles like beneficence and respect for persons. This ongoing process involves assessing physical, psychological, social, and economic risks throughout the trial.

Ethical challenges arise when determining acceptable risk levels and avoiding exploitation of vulnerable populations. Informed consent and equipoise are key safeguards. The application of risk-benefit analysis varies across different trial scenarios, from early-phase cancer drug studies to vaccine trials in low-resource settings.

Principles and Application of Risk-Benefit Analysis in Clinical Trials

Principles of risk-benefit analysis

Top images from around the web for Principles of risk-benefit analysis

• 

  Frontiers | From Clinical Trials to Highly Trustable Clinical Trials: Blockchain in Clinical ... View original

  Is this image relevant?

• 

  Frontiers | Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How? View original

  Is this image relevant?

• 

  Key design considerations for adaptive clinical trials: a primer for clinicians | The BMJ View original

  Is this image relevant?

• 

  Frontiers | From Clinical Trials to Highly Trustable Clinical Trials: Blockchain in Clinical ... View original

  Is this image relevant?

• 

  Frontiers | Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How? View original

  Is this image relevant?

1 of 3

Top images from around the web for Principles of risk-benefit analysis

• 

  Frontiers | From Clinical Trials to Highly Trustable Clinical Trials: Blockchain in Clinical ... View original

  Is this image relevant?

• 

  Frontiers | Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How? View original

  Is this image relevant?

• 

  Key design considerations for adaptive clinical trials: a primer for clinicians | The BMJ View original

  Is this image relevant?

• 

  Frontiers | From Clinical Trials to Highly Trustable Clinical Trials: Blockchain in Clinical ... View original

  Is this image relevant?

• 

  Frontiers | Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How? View original

  Is this image relevant?

1 of 3

• Risk-benefit analysis systematically assesses and balances potential risks and benefits of a clinical trial
• Ensures expected benefits justify risks to participants
• Involves key principles:
  • Beneficence maximizes benefits and minimizes risks (patient welfare)
  • Non-maleficence avoids harm or injury (Hippocratic Oath)
  • Respect for persons protects participant autonomy and obtains informed consent (voluntary participation)
  • Justice ensures fair distribution of risks and benefits among participants (equitable selection)
• Ongoing process throughout trial lifecycle conducted during protocol development, ethics committee review, and trial monitoring
• Continuously reassessed as new safety or efficacy data emerges (adaptive trial design)

Types of clinical research risks

• Physical risks include adverse effects from intervention (medication side effects), invasive procedures (biopsies), or discomfort (pain)
• Psychological risks involve emotional distress, anxiety (fear of unknown), or stigma associated with participation (HIV trials)
• Social risks encompass discrimination, loss of privacy (confidentiality breaches), or impact on relationships (family dynamics)
• Economic risks relate to costs of participation such as travel expenses or time off work (lost wages)
• Risks vary depending on trial phase (higher in early phases), intervention (drug vs. behavioral), and participant population (children, pregnant women)

Ethics of risk-benefit balance

• Ethical challenges arise when balancing risks and benefits
• Determining acceptable risk levels in relation to expected benefits
• Minimizing risks and ensuring they are reasonable considering importance of knowledge gained
• Avoiding exploitation of vulnerable populations (prisoners) or those with limited treatment options (rare diseases)
• Informed consent is key safeguard ensuring participants understand and voluntarily accept risks
  • Participants receive clear, understandable information about potential risks and benefits (plain language)
  • Consent processes emphasize voluntary participation and right to withdraw (no coercion)
• Equipoise, genuine uncertainty about relative merits of interventions, is important ethical principle
  • Trials only conducted when true uncertainty exists about which intervention is superior (standard of care vs. new drug)
  • Lack of equipoise may expose participants to unjustified risks or deny access to proven effective treatments (withholding life-saving therapy)

Application in trial scenarios

1. Phase 1 trial of novel cancer drug with limited preclinical data
   • Risks: unknown safety profile, potential serious adverse effects (organ toxicity), invasive procedures (tumor biopsies)
   • Benefits: potential therapeutic benefit for advanced disease patients with limited options (last resort)
   • Ethical considerations: ensuring voluntary informed consent, close monitoring and safety measures (dose escalation), justifying risks considering potential benefits and scientific importance (proof-of-concept)
2. Placebo-controlled trial of new antidepressant in mild to moderate depression
   • Risks: exposure to placebo, delay in receiving active treatment, potential worsening symptoms (suicide risk)
   • Benefits: contribution to scientific knowledge, access to care and monitoring, potential therapeutic benefit (improved mood)
   • Ethical considerations: ensuring equipoise, minimizing placebo exposure (add-on design), offering active treatment to placebo group after trial (open-label extension), considering alternative trial designs (active comparator)
3. Vaccine trial in low-resource setting with high disease burden
   • Risks: adverse effects (injection site reactions), potential exploitation (undue inducement), limited post-trial vaccine access (affordability)
   • Benefits: potential significant public health impact (herd immunity), capacity building (infrastructure development), access to healthcare (trial site clinics)
   • Ethical considerations: ensuring locally relevant research question, community engagement (participatory approach), fair participant selection (inclusive eligibility), post-trial access plans (government agreements), benefit-sharing with host community (technology transfer)